1. Introduction {#s0005}
===============

Sexually transmitted infections (STIs) are the most common infectious diseases worldwide. According to a 2016 [@b0205], more than 1 million cases are reported every day. STIs are associated with serious reproductive tract health complications, such as ectopic pregnancy, pelvic inflammatory diseases, and infertility. They are also linked to several types of cancers, including cervical, anal, and oropharyngeal cancers ([@b0035]). It is also well known that human papillomavirus (HPV), a double-strand DNA virus, is the causative agent of cervical cancer, the fourth most common cancer in women worldwide, with 530,000 new cases detected annually ([@b0070]).

HPVs are classified according to their oncogenic potential into high risk (HR-HPV) and low risk groups. The high risk group, which currently includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82, has been associated with cervical intraepithelial lesions and may lead to the development of cervical cancer ([@b0065], [@b0055]). The presence of HPV is important but not sufficient to cause cervical cancer, as the persistence of the virus plays an important role in cancer development ([@b0115], [@b0180]). Indeed, HPV persistent infection has been closely associated with progression to carcinoma ([@b0045]). There are many co-factors that help the virus become a persistent infection, and included in this list is infection with one or more other sexually transmitted disease that may increase the risk of having cervical neoplasia. An STI may facilitate the entry of multiple HR-HPVs as well as decrease the host's ability to resolve the HPV infection ([@b0150]). Discovering and removing co-factors that are involved in HPV persistence and development into cervical dysplasia is critical ([@b0095]). Because STIs play an important role as a co-factor in the development of cervical dysplasia and because they may lead to serious reproductive tract complications, any women who has tested positive for HPV should consider undergoing STI screening and needed treatment.

The association between STI and cervical abnormalities has been reported in many studies ([@b0150], [@b0190], [@b0040], [@b0080]). For example, *Chlamydia trachomatis* has been correlated with the severity of abnormal cervical cytology and HPV infection ([@b0135], [@b0165], [@b0160]). Herpes simplex virus infection has been reported with HPV infection, increasing the risk of invasive cervical cancer ([@b0170]), and other STIs, including *Trichomonas vaginalis*, *Mycoplasma* spp., and *Ureaplasma* spp., have also been associated with HPV infection and cervical abnormal cytology ([@b0130], [@b0025], [@b0060], [@b0120], [@b0125]). Despite the results of those previous studies, the status of STI co-infections in Saudi communities is unknown. Therefore, the primary aim of the present study was to investigate whether an association exists between the presence of HPV/STI co-infection in cervical samples and the development of cervical dysplasia among Saudi women.

2. Methods {#s0010}
==========

2.1. Ethical standards and study design {#s0015}
---------------------------------------

The presented retrospective study was approved by the office of Research Affairs at King Faisal Specialist Hospital and Research Centre (RAC \#2180013) and was conducted in accordance with the Declaration of Helsinki. In total, 351 cervical samples were used, where 142 HPV-positive cervical samples were obtained from previous studies, and 209 additional new cervical samples were newly collected from women who attended the Primary Care Clinic at KFSHRC in Riyadh, Saudi Arabia. The inclusion criteria were women who were married, divorced, or widowed, and the exclusion criteria were women who were virgins or pregnant.

For each woman, cervical cytologic samples were collected using a brush (PreservCyt; ThinPrep Pap test Boxborough, MA, USA) for routine Papanicolaou testing and molecular detection experiments. The cytology of each collected sample was also determined and ranged from normal to various stages of abnormality. The stages of the abnormal cytology were identified using the Bethesda classification system in which lesion severity increases from negative for intraepithelial lesion (NIEL), to atypical squamous cells of undetermined significance (ASCUS), to low-grade squamous intraepithelial lesion (LGSIL), to high-grade squamous intraepithelial lesion (HGSIL), and finally to cervical cancer ([@b0175]).

2.2. DNA extraction {#s0020}
-------------------

A 1-ml aliquot of resuspended cells from the cervical sample was centrifuged, and DNA was extracted using a Gentra Puregene Cell Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). The DNA concentration in each sample was estimated using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The quality of the extracted DNA was determined using *β*-globin primers. The amplified polymerase chain reaction (PCR) products were visualized using 1% agarose gels stained with ethidium bromide. The samples were then stored at −80 °C until required for further processing.

2.3. HPV detection and genotyping {#s0025}
---------------------------------

Nested PCR was preformed to detect HPVs, using primers MY09/MY11 and GP5+/GP6+, which target a sequence located within the L1 region. The first round of PCR was performed using the MY09/MY11 primer set that targeted a 450-bp conserved sequence. The second round was performed using the GP5+/GP6+ primer set targeting a 150-base pair sequence within the 450-base pair product. The PCR conditions for the first round were as follows: 95 °C for 5 min; 35 cycles of 95 °C for 40 s, 54 °C for 40 s, and 72 °C for 40 s, and a final extension at 72 °C for 5 min. The PCR conditions for the second round were as follows: 95 °C for 5 min; 40 cycles of 95 °C for 1 min, 54 °C for 1 min, and 72 °C for 1 min, and a final extension at 72 °C for 5 min. The positive controls were HeLa cells. UltraPure DNase/RNase-free water used as a negative control, and a β-globin control primer set was used as an internal control ([@b0085]).

For HPV genotyping, a GenoFlow HPV assay Kit (DiagoCor Bioscience Incorporation Limited, Hong Kong, China) was used. This kit enables the identification of HPV genotypes associated with cervical cancer. In total, 33 HPV high-risk and low-risk genotypes can be identified with this kit, including HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 66, 68, 70, 71, 72, 73, 81, 82, and 84. A universal probe was also included to detect rare HPV subtypes outside the 33-genotype panel. Target DNA was mixed with a biotin-labeled primer mix and DNA Taq polymerase provided with the kit and was followed by the PCR amplification step using the thermocycling conditions provided by the manufacturer. The PCR products were then denatured and hybridized to HPV-specific DNA, capturing probes via flow- through hybridization. The hybridized DNA was detected by colorimetric development ([@b0200]).

2.4. STIs detection {#s0030}
-------------------

For STI detection, a Genoflow STD array test kit (Hong Kong, China) was used that enables the identification of 11 sexually transmitted common pathogens, namely, *Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum*, herpes simplex virus types 1 and 2, human papillomavirus types 6 and 11. This test is based on PCR and hybridization technology. After amplification of the target DNA with specific primers, the amplicons were hybridized using flow-through hybridization according to manufacturer's instructions. The results were visualized by colorimetric detection.

2.5. Statistical analysis {#s0035}
-------------------------

Data were analyzed using the Statistical Analysis System (SAS), version 9.4. Descriptive and inferential statistics were conducted between variables of interest by demographic and clinical data. Nonparametric tests such as chi-squared test, logistic regression, and Wilcoxon rank-sum of scores test were used to overcome the small sample size. Pearson's chi-squared test was conducted between variables to test for associations. Logistic models were created to test for a correlation between the categorical variables. A 2-sided *P* \< 0.05 was considered statistically significant.

3. Results {#s0040}
==========

Data from 351 participants were analyzed. The median age of the participants was 43 years (range from 19 to 83 years). The majority of the participants (85%) were married. The demographic and clinical characteristics of the participants are summarized in [Table 1](#t0005){ref-type="table"}.Table 1Demographic and clinical data analysed by STI status.STI positive (n = 94) % (26.78)STI Negative (n = 257) % (76.86)Total (n = 351)Chi-square (P value)Age, years(N) %(N) %(N) %Age \< 20 (n = 1)NA0.3 (1)0.3 (1)2.70 (0.61)21--30 (n = 43)4.3 (15)8.0 (28)12.3 (43)31--40 (n = 108)8.3 (29)22.5(79)30.8 (108)41--50 (n = 78)6.3 (22)26.5 (93)22.2 (78)Age \> 50 (n = 121)8 (28)26.5 (93)34.5 (121)  *Marital Status*Married (n = 298)24.5 (86)60.4 (212)84.9 (298)4.79(0.091)Divorced (n = 26)1.4 (5)6.0 (21)7.4 (26)Widowed (n = 27)0.9 (3)6.8 (24)7.7 (27)  *Nationality*Saudi (n = 293)23.1 (81)60.4 (212)83.5 (293)0.67(0.41)Non-Saudi (n = 58)3.7 (13)12.8 (45)16.5 (58)  *Religion*Muslim (n = 318)24.8 (87)65.8 (231)90.6 (318)0.813(0.66)Christian (32)2.0 (7)7.1 (25)9.1 (32)Other (n = 1)NA0.3 (1)0.3 (1)  *Smoking Status*Smoker (n = 21)1.9 (5)6.2 (16)8.1 (21)0.33(0.56)Non-Smoker (n = 238)27.4 (71)64.5 (167)91.9 (238)UNK (n = 92)

The overall prevalence of STIs in the 351 cervical samples was 26.78% (94 positives). The most common pathogens were *Ureplasma urealyticum* /*Ureplasma parvum* (21.1%; n = 7 4; *P* \< 0.05) followed by *Mycoplasma hominis* (4.27%; n = 15; *P* \< 0.05), and Human papillomavirus types 6 and 11 (1.9%; n = 7).

The general distribution of the cases by STI presence or absence is shown in [Table 1](#t0005){ref-type="table"}. Of 351 women included in the study, 142 previously tested positive for HPV and thus were included in the following analysis. Of these, 70 women (49.2%) tested positive for HPV 16, 36 women (25.3%) tested positive for HPV 18, and 10 women (7.0%) tested positive for HPV 31. The most common HPV genotypes were HPV 16 followed by HPV 18.

The results of cytology testing showed that 256 of the cervical samples (72.9%) were normal, 6 samples (1.7%) were classified as ASCUS (Atypical Squamous Cells of Unknown Significance), 12 samples (3.4%) were LGSIL (Low-Grade Squamous Intraepithelial Lesion), 22 samples (6.2%) were HGSIL (High-grade squamous intraepithelial lesion), and 55 samples (15.6%) were cervical cancer. The HPV status for those patients is summarized in [Table 2](#t0010){ref-type="table"}. A significant association between cytology grades and HPV status was found (*P* \< 0.005).Table 2Association between STIs and clinical diagnosis[a](#tblfn1){ref-type="table-fn"} by cytology grades, test of association was conducted, and the P value is reported.Variables N (%)NormalASCUSLGSILHGSILCervical cancerChi Test P Value*HPV*Positive (142,40.5%)\
Negative (209,59.5%)52(14.8%)\
204(58.1%)2(0.6%)\
4(1.2%)11(3.1%)\
1(0.3%)21(6%)\
1(0.3%)54(15.4%)\
1(0.3%)\<0.001[\*\*](#tblfn5){ref-type="table-fn"}\
  *STI Panel*[b](#tblfn2){ref-type="table-fn"}Positive (94,26.8%)\
Negative (257,73.2%)72(20.5%)\
184(52.4%)3(0.9%)\
3(0.9%)5(1.4%)\
7(2.0%)3(0.9%)\
19(5.4%)11(3.1%)\
44(12.5%)0.17  *STI Type*[c](#tblfn3){ref-type="table-fn"}0.005[\*\*](#tblfn5){ref-type="table-fn"}Pathogenic (12,12.8%)\
Opportunistic (82,87.2%)5(5.3%)\
67(71.3%)2(2.1%)\
1(1.1%)3(3.2%)\
2(2.1%)1(1.1%)\
2(2.1%)2(2.1%)\
9(9.6%)\
  *UU/UP*Positive (74,21.1%)\
Negative (277,78.9%)63(18%)\
193(55%)2(0.6%)\
4(1.1%)1(0.3%)\
11(3.1%)1(0.3%)\
21(6.0%)7(2.0%)\
48(13.7%)0.049[\*](#tblfn4){ref-type="table-fn"}  *TV*NAPositive (1,0.3%)\
Negative (350,99.7%)1(0.3%)\
255(72.7%)NA\
6(1.7%)NA\
12(3.4%)NA\
22(6.3%)NA\
55(0.7%)  *MH*Positive (15,4.3%)\
Negative (336,95.7%)8(2.3%)\
248(70.7%)1(0.3%)\
5(1.4%)3(0.9%)\
9(2.7%)1(0.3%)\
21(6.0%)2(0.6%)\
53(15.1%)0.003[\*\*](#tblfn5){ref-type="table-fn"}  *CT*Positive (7,2%)\
Negative (344,98%)5(1.4%)\
251(71.5%)NA\
6(1.7%)2(0.57%)\
10(2.9%)NA\
22(6.3%)NA\
55(15.7%)0.005[\*\*](#tblfn5){ref-type="table-fn"}  *NG*Positive (1,0.3%)\
Negative (350,99.7%)1(0.3%)\
255(72.7%)NA\
6(1.7%)NA\
12(3.4%)NA\
22(6.3%)NA\
55(0.7%)NA\
[^1][^2][^3][^4][^5]

Of the 142 HPV-positive samples, 36 (25.35%) also tested positive for an STI (odds ratio 25, *P* \< 0.001). The most common STIs in the HPV-positive samples were *Ureplasma urealyticum* /*Ureplasma parvu* (13.38%; n = 19, odds ratio 0.43, *P* \< 0.01), followed by *Mycoplasma hominis* (6.3%; n = 9), and HPV types 6 and 11 (4.2%; n = 6) ([Table 3](#t0015){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}). It is worth noting that the STI panel used in this study detects only 2 type of HPVs, namely, HPV types 6 and 11, both of which are low-risk HPVs, whereas the GenoFlow HPV array kits detects 33 high- and low-risk HPVs.Table 3Association between clinical diagnosis and HPV status.Variable N (%)HPV Positivehpv NegativeChi-Square P ValueOR (95% CI)(OR) P Value*STI Panel*[a](#tblfn6){ref-type="table-fn"}Positive (94,26.8%)\
Negative (257,73.2%)36(10.3%)\
106(30.2%)58(16.5%)\
151(43.0%)0.620.884 (0.5--1.4)\
10.62  *STI Type*[b](#tblfn7){ref-type="table-fn"}Pathogenic (12,12.8%)\
Opportunistic (82,87.2%)11(11.7%)\
25(26.6%)1(1.1%)\
57(60.6%)\<0.0001^\*\*\*^25 (3.1--204.9)\
1\<0.0001^\*\*\*^  *UU/UP*Positive (74,21.1%)\
Negative (277,78.9%)19(5.4%)\
123(35.0%)55(15.7%)\
154(43.9%)0.004[\*\*](#tblfn8){ref-type="table-fn"}0.4(0.2--0.8)\
10.003[\*\*](#tblfn8){ref-type="table-fn"}  *TV*Positive (1,0.3%)\
Negative (350,99.7%)1(0.3%)\
141(40.2%)NA\
209(59.6%)NANANA  *MH*Positive (15,4.3%)\
Negative (336,95.7%)9(2.6%)\
133(37.9%)6(1.7%)\
203(57.8%)0.122.28(0.8--6.6)\
10.12  *CT*Positive (7,2.0%)\
Negative (344,98%)2(0.6%)\
140(39.89%)140(39.9%)\
204(58.1%)0.220.58(0.1--3.0)0.51  *NG*Positive (1,0.3%)\
Negative (350,99.7%)1(0.3%)\
141(40.2%)NA\
209(59.5%)NANANA[^6][^7][^8][^9]Fig. 1Distribution of sexually transmitted infections (STIs) by HPV status. The STIs were detected by the DiagCor GenoFlow sexually transmitted disease panel. The kit detects 11 types of STI pathogens, including HPV-6, HPV-11, TV, CT, NG, UU, UP, MG, MH, HSV-1, and HSV-2. The highest detected organism is UU/UP, followed by MG, and HPV 6 and 11.

The results of a chi-square test indicated that there was an association between STI and HPV.

The distribution of cases by cervical cytology grades and STI presence is shown in [Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}, and [Table 4](#t0020){ref-type="table"}. Abnormal cervical cytology grades were associated with detection of pathogenic STIs (odds ratio 6.3, *P* \< 0.001). Most of the 351 samples were negative for HPV and had normal cytology. Seventy two samples (20.5%) were positive for STI and also had normal cytology.Fig. 2Distribution of cases by cervical cytology grade and the presence of sexually transmitted infection (STI). Most of the cases are normal, while 20.5% have a normal cytology grade and are positive for an STI. Of the cervical cancer cases, 12.5% have no STI, and 3.1% are positive for an STI.Table 4Association between cytology results (Abnormal includes: ASCUS, LGSIL, HGSIL, and cervical cancer) and STIs.Variable N (%)Abnormal cytologyNormal cytologyChi-Square P ValueOR (95% CI)OR P Value*STI Panel*[a](#tblfn9){ref-type="table-fn"}Positive (94,26.8%)\
Negative (257,73.2%)22(6.3%)\
73(20.8%)72(20.5%)\
184(52.4%)0.350.77(0.44--1.33)\
10.35  *STI Type*[b](#tblfn10){ref-type="table-fn"}Pathogenic (12,12.8%)\
Opportunistic (82,87.2%)7(7.6%)\
15(15.9%)5(5.3%)\
67(71.3%)0.002[\*\*](#tblfn11){ref-type="table-fn"}6.3(1.7--22.4)\
10.0048[\*\*](#tblfn11){ref-type="table-fn"}\
  *UU/UP*Positive (74,21.1%)\
Negative (277,78.9%)11(3.1%)\
84(23.9%)63(18%)\
193(55%)0.008[\*\*](#tblfn11){ref-type="table-fn"}0.4(0.2--0.8)\
10.005[\*\*](#tblfn11){ref-type="table-fn"}  *TV*Positive (1,0.3%)\
Negative (350,99.7%)NA\
95(27.1%)1(0.3%)\
255(72.7%)NANANA  *MH*Positive (15,4.3%)\
Negative (336,95.7%)7(1.99%)\
88(25.1%)8(2.3%)\
248(70.7%)0.082.46 (0.86--6.99)\
10.01  *CT*Positive (7,2.0%)\
Negative (344,98%)2(0.57%)\
93(26.5%)5(1.42%)\
251(71.5%)0.931.1(0.21--5.67)0.93  *NG*Positive (1,0.3%)\
Negative (350,99.7%)1(0.3%)\
95(27.1%)NA\
255(72.7%)NANANA  *HPV Status*Positive (142,40.5%)\
Negative (209,59.5%)5(1.4%)\
90(25.6%)52(14.8%)\
204(58.1%)\<0.0001^\*\*\*^70.6(27.3--182.7)\
1\<0.0001^\*\*\*^[^10][^11][^12][^13]

Supplementary Table 1 shows the correlation model in predicting diagnosis by HPV status and STI infection. The age distribution by clinical data is shown in [Table 5](#t0025){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}, the only significance of age was only found by HPV status, positive patients were mostly older than negative patients.Table 5Age distribution (mean & standard deviation) by clinical data. Wilcoxon Sum of Scores Test was conducted to see if age was significantly different in the clinical data.Variables N (%)Mean age (SD)Wilconxin sum of scores test (P value)*STI Panel*Positive\
Negative43.65(13.35)\
46.23(14.01)0.143  *STI Type*Pathogenic\
Opportunistic39.1(10.12)\
44.32(13.68)0.257  *HPV Status*Positive\
Negative47.93(13.84)\
43.92(13.79)0.006\*\*  *UU/UP*Positive\
Negative44.67(13.79)\
45.77(13.90)0.512  *TV*Positive\
Negative25(NA)\
45.60(13.84)NA  *MH*Positive\
Negative40.66(12.63)\
45.76(13.89)0.20  *CT*Positive\
Negative37.71(10.85)\
45.70(13.88)0.141  *NG*Positive\
Negative43(NA)\
45.5(13.86)NAFig. 3(A) Distribution of age by HPV status and cytology grade. Women who are positive for HPV and have abnormal cytology grades are older than the other women. (B) Distribution of age by sexually transmitted infection (STI) status and cytology grade. Women with ASCUS or HGSIL who are positive for STIs are younger. For LGSIL and cervical cancer, most of the women who are positive for STIs are older than those in the group negative for STIs.

4. Discussion {#s0045}
=============

The present study aimed to investigate the association of HPV/STI co-infection with cervical dysplasia. Co-infection with an STI has been suggested to be a cofactor in HPV persistence and neoplasia progression. These STIs include viral infections, such as herpes simplex virus type 2 and human papillomavirus, bacterial infections, such as *Chlamydia trachomatis*, *Neisseria gonorrhoeae,* and *Mycoplasma* spp*.,* and infection with the protozoan *Trichomonas vaginalis*. Many studies have recognized an association between STIs, HPV infection, and cervical dysplasia especially cervical cancer, showing that the HPV rate is significantly higher among women with STIs ([@b0195], [@b0095], [@b0100]). By contrast, a few studies have shown that STI has no association with HPV, abnormal cytology, or cervical cancer. The lack of an association may be attributable to the absence of some relevant information and inaccuracies in self-reported information. Some authors have suggested further studies with larger sample sizes to confirm the associations between pathogens ([@b0210]).

The role of an STI as an HPV cofactor is to facilitate entry and persistence of HPV through chronic cervical inflammation and ulceration in the cervical epithelium as well as through a reduction in host cell--mediated immunity caused by the STI ([@b0190]).

The overall prevalence of STIs in the 351 samples examined in the present study was 27%, which is consider low in comparison with that from previous studies in other counties that have tested for the prevalence of STIs in healthy women, for example, in Mexico (57.7%) and Korea (49.2%) ([@b0105], [@b0140]). Overall, the kingdom lacks current national statistics of STI prevalence; the most recent retrospective study conducted in Saudi Arabia in 2015 analyzed the annual number of STI cases from 2005 to 2012. The data for that study were obtained from the Ministry of Health in Saudi Arabia, and the main finding was that STIs in Saudi Arabia remain low, with an annual incidence of 92.1 cases per 100,000 persons ([@b0145]).

The present study results were inconsistent with those from a previous prospective case-control study that aimed to measure the prevalence of STIs in fallopian tubes collected from 135 Saudi women with ectopic pregnancy ([@b0020]). That study observed that STIs were detected in the upper genital tract in 31.8% of the Saudi women. The difference between the present study and that study is the site of sample collection. The present study targeted the lower genital tract, whereas the previous study targeted the upper genital tract. In addition, the sampling technique differed between that study and the present study. In the present study, the most commonly detected pathogens were *Ureplasma urealyticum*/*Ureplasma parvom*, *Mycoplasma hominis*, and HPV types 6 and 11. This finding is consistent with that of a pervious study showing that the *Mycoplasmataceae* family, including the two genera *Mycoplasma* spp. and *Ureaplasma* spp., were the most common reported STI pathogens. These two bacteria are important opportunistic pathogens of the female lower genital tract ([@b0190]). The role of these pathogens as a risk factor in cervical dysplasia progression has not been completely studied. The presence of these infections may play a role in initiating cellular anomalies and in viral persistence (28). Indeed, some authors ([@b0190], [@b0100]) have suggested that the presence of a high density of *U. urealyticum,* greater than 10^4^ CCU/mL, may be a risk factor for HPV infection in asymptomatic women.

In the present study, the most common HPV genotypes detected were HPV 16 (49.2%) followed by HPV 18 (25.3%). This result is similar to two previous studies in Saudi Arabia showing that the most prevalent types included HPV 18, 16, 31, 58, 56, and 42 (33, 34). As we anticipated, we found a strong association between HR-HPV and abnormal cervical cytology, which agrees with previous studies ([@b0185], [@b0090]).

The present study found that HPV infection was more frequent among women with older age, and patients diagnosed with cervical cancer had the oldest age followed by patients with HGSIL and ASCUS. Kjaer and colleagues found that women 30 years of age and younger have a better ability to clear HPV infection than those infected after the age of 30 ([@b0155]). As a result, women older than 30 are more likely to develop a persistent HPV infection and then to develop cervical cancer ([@b0110]). [@b0030] showed that the prevalence of HPV is high in older women. The lack of a screening program in Saudi Arabia plays a role in this finding because HPV infection may be asymptomatic.

For STIs, women who have ASCUS and HGSIL were younger than women with LGSIL and cervical cancer. In our study, STIs were more prevalent among women older than 40 years and thus is inconsistent with previous studies that have suggested that STIs are associated with young, sexually active women. These results can be attributable to religious and cultural beliefs that prevent sexual relations before marriage ([@b0075], [@b0095]).

However, the main finding of the present study was that there was a significant association between STI (especially *Ureplasma* spp. and *Mycoplasma hominis*), HR-HPV, and abnormal cervical cytology. The overall percentage of STIs in the HPV-positive samples was 25.35%, and 3.1% of the samples with cervical cancer were positive for STIs. These findings support a number of previous studies that have found correlations among STIs, HR-HPV, and cervical dysplasia. For example, a cross-sectional study in Korea of 800 women who underwent liquid-based cervical cytology analysis shows an association not only between STIs and HR-HPV infection but also between abnormal cervical cytology and STIs, suggesting that cytological changes diagnosed as ASCUS in women without HR-HPV could be false-positives due to inflammation and changes of cervical epithelial cells induced by the STIs because some STIs can change the size and shape of cervical epithelial cells. However, the present study did not support an association between cervical cytology and STIs ([@b0095]). An epidemiology study in Greece that enrolled 345 women who visited a gynecology clinic for routine cervical screening found an association between *Ureaplasma* spp. and HR-HPV infection ([@b0155]). By contrast, an epidemiological study in China ([@b0210]) that included 1218 married women did not support any association between presence of HR-HPV and *T. vaginalis*, *C. trachomatis*, and *U. urealyticum*. Another study conducted in Mexico showed that there was no meaningful association between STIs and HR-HPV infection ([@b0140]).

Although several studies have shown an association between *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* and the presence of HPV as well as the development of cervical dysplasia ([@b0015], [@b0195], [@b0050]), the present study results did not support that association; however, the low number of positive cases affecting the results made it difficult to find statistical significance.

Our study found a significant association between cervical cytology diagnosis and HPV status, STI type (opportunistic and pathogenic), the presence of *Ureaplasma* spp., and *Mycoplasma hominis* (P \< 0.05). It is important to note that the presence of an STI is recognized as one of the risk factors associated with cervical cancer, and it is important to conduct STI screening tests on HPV-positive women. STIs have been associated with an inflammatory response and alteration in the epithelial cells of the cervix that help the entry of HPV. Moreover, STIs are associated with changes in the immunological response pathways and thus may have an impact on an individual's susceptibility to other pathogens; this may lead to a decreased ability to clear HPV from the cervix and help the persistence of the infection.

5. Conclusion {#s0050}
=============

The present study found an association between HR-HPV/STI co-infection and abnormal cervical cytology. However, we suggest that further investigation is needed with a larger sample size obtained over a longer period of time and from a more widespread Saudi population. In Saudi Arabia, the reported cases of STIs are low due to the conservative culture and perceived shame of visiting a healthcare professional for such a disorder. Although sexual behaviors and societal norms may reduce individual exposure to STIs, awareness and prevention of STI remains important to avoid future complications.
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[^1]: Cervical cytology grades was assigned by histology lab (ASCUS = Atypical Squamous Cells of Unknown Significance, LGSIL = Low-grade squamous intraepithelial lesion, HGSIL = High-grade squamous intraepithelial lesion).

[^2]: Sexually transmitted infections (STIs) detect by *DiagCor* GenoFlow hybridization STD assay.

[^3]: sexually transmitted infections (STIs)Types (**opportunistic** organisms include Ureaplasma (Urealyticum (UU), Parvum (UP)) and mycoplasmas (Genitalium (MG) and Hominis (MH)), while the the **pathogenic** organisms include Trichomonas Vaginalis (TV) , Chlamydia Trachomatis (CT), and Neisseria Gonorrhoeae (NG).

[^4]: P value is less than 0.01.

[^5]: P Value is less than 0.001.

[^6]: \*P value is less than 0.01.

[^7]: Sexually transmitted infections (STIs) detected by *DiagCor* GenoFlow hybridization STD assay.

[^8]: STI types are **opportunistic** organisms, including *Ureaplasma urealyticum* (UU), *Ureaplasma parvum* (UP), *Mycoplasma genitalium* (MG), and *Mycoplasma hominis* (MH), as well as **pathogenic** organisms, including *Trichomonas vaginalis* (TV), *Chlamydia trachomatis* (CT), and *Neisseria gonorrhoeae* (NG)..

[^9]: P Value is less than 0.001.

[^10]: \*P value is less than 0.01.

[^11]: Sexually transmitted infections (STIs) detected by *DiagCor* GenoFlow hybridization STD assay.

[^12]: STI types are **opportunistic** organisms, including *Ureaplasma urealyticum* (UU), *Ureaplasma parvum* (UP), *Mycoplasma genitalium* (MG), and *Mycoplasma hominis* (MH), as well as **pathogenic** organisms, including *Trichomonas vaginalis* (TV), *Chlamydia trachomatis* (CT), and *Neisseria gonorrhoeae* (NG).

[^13]: P Value is less than 0.001.
